Dr. Reddy's Laboratories
223 hedge funds and large institutions have $1.7B invested in Dr. Reddy's Laboratories in 2023 Q4 according to their latest regulatory filings, with 38 funds opening new positions, 81 increasing their positions, 66 reducing their positions, and 25 closing their positions.
5,226% more call options, than puts
Call options by funds: $1.86M | Put options by funds: $35K
150% more funds holding in top 10
Funds holding in top 10: 2 → 5 (+3)
52% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 25
23% more repeat investments, than reductions
Existing positions increased: 81 | Existing positions reduced: 66
12% more capital invested
Capital invested by funds: $1.51B → $1.7B (+$187M)
7.69% more ownership
Funds ownership: 65.36% → 73.05% (+7.7%)
6% more funds holding
Funds holding: 211 → 223 (+12)
Top Buyers
| 1 |
Morgan Stanley
New York
|
+$60.2M |
| 2 |
Man Group
London,
United Kingdom
|
+$51.2M |
| 3 |
BlackRock
New York
|
+$34.6M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$10.6M |
| 5 |
Schroder Investment Management Group
London,
United Kingdom
|
+$7.79M |
Top Sellers
| 1 |
Millennium Management
New York
|
-$22.9M |
| 2 |
GQG Partners
Ft. Lauderdale,
Florida
|
-$19.1M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
-$15.8M |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$14.7M |
| 5 |
Goldman Sachs
New York
|
-$9.38M |
RDY Hedge Fund Activity: Q4 2023 in Review
223 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Dr. Reddy's Laboratories (RDY) for Q4 2023, worth a combined $1.7B — up 12% from $1.51B a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new RDY positions and 25 closed out — a net gain of 13 holders — while 81 added to existing stakes and 66 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $60.2M. The largest seller was Millennium Management, cutting an estimated $22.9M.
- 223 institutional investors held Dr. Reddy's Laboratories (RDY) as of Q4 2023, up from 211 in Q3 2023.
- Funds reported $1.7B of Dr. Reddy's Laboratories stock for Q4 2023, up 12% quarter-over-quarter.
- 38 funds opened new Dr. Reddy's Laboratories positions in Q4 2023 and 25 closed out, a net change of +13 holders.
- The largest Dr. Reddy's Laboratories buyer in Q4 2023 was Morgan Stanley, an estimated $60.2M added.
- The largest Dr. Reddy's Laboratories seller in Q4 2023 was Millennium Management, an estimated $22.9M sold.
Based on aggregated 13F filings for Q4 2023.